A commercial 5-h direct herpes simplex virus (HSV) antigen detection enzyme immunoassay kit (Du Pont Herpchek) was compared with a cell culture isolation system by using primary rabbit kidney and MRC-5 cells with 779 clinical specimens received in virus transport medium and with stock tissue culture preparations of HSV types 1 and 2. In the first study of 422 specimens from symptomatic patients, Herpchek detected 110 of 111 HSV-positive specimens (26.3% of all specimens), with a sensitivity of 99% and a specificity of 100%. In the second study of 357 specimens primarily from asymptomatic pregnant women, however, Herpchek detected 70 of 119 HSV-positive specimens (33% of all specimens), with a sensitivity of 58.8% and a specificity of 99.5%. Stock virus dilution experiments showed that Herpchek was 10 to 100 times less sensitive than culture. Herpchek was found to be an acceptable test for symptomatic patients, but for symptomatic patients shedding a low titer of HSV it was not as sensitive and cell culture of Herpchek-negative specimens is recommended for such cases.
The Du Pont enzyme-linked immunosorbent assay (ELISA) for herpes simplex virus (HSV), Herpchek, a rapid diagnostic test for HSV directly from specimens from patients, has been reported to have a sensitivity and a specificity similar to those of HSV isolation in cell culture (2, 4, 5, 8, 12) . This test has been licensed for direct diagnosis of symptomatic HSV-infected patients by the Food and Drug Administration as long as the swab specimen was obtained in the proprietary lysing transport medium Herptran. Because Herptran renders the specimen unsuitable for virus isolation, all previously published comparative studies required that dual specimens, one in Herptran and one in standard virus transport medium (VTM), be obtained. Difficulty in obtaining dual specimens led to an evaluation of this new ELISA using specimens obtained in conventional VTM. Before the Herpchek test was done, a sample of the single specimen in VTM was treated with concentrated (10x) Herptran. Two split-sample studies comparing ELISA and culture were done with 779 specimens from patients. In addition to these specimens, comparisons were performed on stock HSV type 1 (HSV-1) and HSV-2 preparations at various dilutions.
MATERIALS AND METHODS
Specimens from patients. In the first study, 422 specimens, each in a plastic centrifuge tube containing 2 ml of VTM (Bartels Immunodiagnostics), were received at a large commercial diagnostic laboratory within 1 to 2 days after the specimens were taken from the patients. Physicians swabbed lesions with Dacron swabs and broke and left the swabs in the VTM, which was transported cold to the laboratory. The VTM contained minimum essential medium with nonessential amino acids and L-glutamine, Hank salts, fetal bovine serum (2%), gentamicin (10 ,ug/ml), streptomycin (50 ,ug/ml), penicillin (50 ,ug/ml), amphotericin B (4 ,ug/ml), HEPES Blocking antibody. Specimens found to be positive by direct ELISA (Herpchek) that were culture negative were tested for the presence of HSV antigen by a blocking antibody test using human serum (HSV immune and nonimmune) obtained from Boston Biomedica with anti-HSV-1 ELISA antibody titer signal-to-cutoff ratios ranging from 4.0 to 5.8 and anti-HSV-2 ELISA antibody titer signal-to-cutoff ratios ranging from 1.2 to 4.1. Samples (100 pul) of ELISApositive, culture-negative specimens were mixed with 10 ,ul each of immune and nonimmune sera, incubated at room temperature for 30 min, and then tested in a Herpchek ELISA. Greater than 50% reduction in the optical density (OD) readings of the ELISAs of specimens treated with immune and nonimmune sera was considered confirmation of HSV antigen in the sample.
RESULTS
Studies with specimens from patients. Culture and ELISA results of 422 specimens from patients were compared in the first study. Four specimens negative by culture but indeterminate by Herpchek were not included. In the second study, 357 more specimens from patients, predominantly pregnant women, were compared. Table 1 shows the results. Of 119 culture-positive specimens (33%) of 355 specimens, Herpchek detected 70, while 10 of 11 specimens that were culture negative but Herpchek positive were confirmed by blocking. This gave a sensitivity of 58.8% (70 of 119) and a specificity of 95.3% (227 of 238). Specificity after correction for blocking was 99.5% (237 of 238).
To help verify the 49 ELISA-negative, culture-positive results, 15 ELISA-negative, culture-positive specimens were retested by Herpchek and all 15 were again negative. Cells harvested from these 15 cultures with a typical HSV CPE were highly positive when tested by Herpchek and were typed by monoclonal antibody to HSV-1 and HSV-2 in an immunofluorescence test, confirming that cell cultures that had been found negative twice by the Herpchek test were infected with HSV. Of the 119 HSV-positive samples isolated, 60 (50.4%) contained HSV-1 and 59 (49.5%) contained HSV-2. When the virus types in those detected and those missed by Herpchek were analyzed, a big difference was found. Of the 70 virus isolates detected by Herpchek and culture, 25 (35.7%) were HSV-1 and 45 (64.2%) were HSV-2. Of the 49 virus isolates that were missed by Herpchek and were culture positive, 35 (71.4%) were HSV-1 and 14 (28.5%) were HSV-2. The virus titers of the 119 isolates were estimated by the number of days until an HSV CPE was detected in culture ( (2, 4, 5, 8, 12) . However, in a second study of 357 additional specimens, the sensitivity of Herpchek was much lower (58.8%). In both studies, specificity was very good when corrected by blocking antibody studies.
To explain these findings, an analysis of the second experiment was done. First, the types of specimens tested in the two experiments, although in both cases predominantly from females of childbearing age, were different. In the first experiment, most of the specimens were of high titer and from symptomatic patients seeking confirmation of HSV infection. In the second experiment, most of the specimens were from women presumed asymptomatic and being screened during pregnancy.
Second, the HSV titer in symptomatic herpes lesions has been reported to range from 103 to 106, with female genital lesions showing less than 103 (1, 7, 9) . In asymptomatic virus-shedding patients, the titer has been reported to be 10 to 100 times lower (3). Studies using nonclinical stock virus preparations showed that Herpchek was less sensitive than culture. Selected specimens from patients, when diluted, also showed Herpchek to be less sensitive than culture. Of the 49 clinical virus isolates missed by Herpchek, 46 were of low titer. Another interesting finding was that of the 49 HSV isolates missed, 35 (71%) were HSV-1. With the nonclinical stock virus preparation, Herpchek detection was less sensitive for HSV-1 than for HSV-2.
In both experiments, Herpchek picked up noncultivable HSV antigens, as proven by the blocking experiments. There is no way to tell whether virus was noninfectious when swabbed from a lesion of a patient or whether it died in transport to the laboratory. Also, the clinical significance of noninfectious virus antigen is hard to determine. Dried up, dead virus antigen that is not infectious would not warrant a cesarian section to prevent exposure of a newborn (6), but many physicians might do a cesarian section, since they may not believe that the HSV antigen was noninfectious.
It is concluded from these experiments that Herpchek is a very sensitive ELISA for symptomatic herpes lesions, even when the specimen is collected in VTM instead of the proprietary Herptran transport medium. In such cases, culture backup may not be needed since the sensitivity of Herpchek is close to 100%, but when specimens are taken from asymptomatic patients, such as in screening of pregnant women, culture backup is absolutely necessary. Without culture, many low-titer virus infections will be missed. How clinically significant these low-titer virus infections are has yet to be determined.
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